Teru Hideshima

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
    Abdel Kareem Azab
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4341-51. 2009
  2. pmc IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
    Hiromasa Hideshima
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Int J Oncol 44:1171-6. 2014
  3. pmc A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, USA
    Ther Clin Risk Manag 4:129-36. 2008
  4. doi request reprint Histone deacetylase inhibitors in the treatment for multiple myeloma
    Teru Hideshima
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA
    Int J Hematol 97:324-32. 2013
  5. pmc Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    Semin Hematol 49:223-7. 2012
  6. pmc Preclinical studies of novel targeted therapies
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:1071-91, viii-ix. 2007
  7. doi request reprint Novel therapies in MM: from the aspect of preclinical studies
    Teru Hideshima
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
    Int J Hematol 94:344-54. 2011
  8. doi request reprint Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
    Teru Hideshima
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Mol Cancer Ther 10:2034-42. 2011
  9. ncbi request reprint Current therapeutic uses of lenalidomide in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Investig Drugs 15:171-9. 2006
  10. pmc A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
    Gullu Gorgun
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 115:5202-13. 2010

Detail Information

Publications98

  1. pmc CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
    Abdel Kareem Azab
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 113:4341-51. 2009
    ..These experiments provide a proof of concept for the use of agents that disrupt interaction with the microenvironment for enhancement of efficacy of cytotoxic agents in cancer therapy...
  2. pmc IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
    Hiromasa Hideshima
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Int J Oncol 44:1171-6. 2014
    ..Finally, we demonstrated that IKKβ inhibitor enhanced cytotoxicity, associated with inhibition of NF-κB activity induced by bortezomib in MCF7 and T47D breast cancer cells. ..
  3. pmc A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School Boston, MA, USA
    Ther Clin Risk Manag 4:129-36. 2008
    ..Specifically, the combination improved overall and extent of response, as well as prolonged time to progression and overall survival, resulting in FDA approval of lenalidomide with Dex for therapy MM relapsing after prior therapy...
  4. doi request reprint Histone deacetylase inhibitors in the treatment for multiple myeloma
    Teru Hideshima
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA
    Int J Hematol 97:324-32. 2013
    ..Many HDAC inhibitors have already shown significant anti-MM activities in preclinical studies and are under evaluation in clinical trials...
  5. pmc Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA
    Semin Hematol 49:223-7. 2012
    ..Importantly, multiple myeloma (MM) cells are considered to have lower threshold against these stresses than other cell types, which makes these cells sensitive to proteasome inhibitors...
  6. pmc Preclinical studies of novel targeted therapies
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 21:1071-91, viii-ix. 2007
    ....
  7. doi request reprint Novel therapies in MM: from the aspect of preclinical studies
    Teru Hideshima
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
    Int J Hematol 94:344-54. 2011
    ..Currently they are under evaluation in preclinical studies, as single agents and/or in combination, to improve outcome of MM patients...
  8. doi request reprint Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
    Teru Hideshima
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Mol Cancer Ther 10:2034-42. 2011
    ..Data from the studies summarized here have been used as the rationale for the implementation of phase II and III clinical trials of DACi, alone and combined with bortezomib, in relapsed and refractory multiple myeloma...
  9. ncbi request reprint Current therapeutic uses of lenalidomide in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Expert Opin Investig Drugs 15:171-9. 2006
    ..Therefore, lenalidomide represents a new class of antitumour agents that is useful in the treatment of MM. Lenalidomide has received fast track designation from the FDA for the treatment of MM and myelodysplastic syndromes...
  10. pmc A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
    Gullu Gorgun
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 115:5202-13. 2010
    ..MLN8237 is currently in phase 1 and phase 2 clinical trials in patients with advanced malignancies, and our preclinical results suggest that MLN8237 may be a promising novel targeted therapy in MM...
  11. ncbi request reprint Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment
    Toshiaki Hayashi
    The Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 1:851-60. 2002
    ..These studies provide the rationale for clinical trials of As2O3, either alone or together with dexamethasone, to overcome classical drug resistance and improve outcome in patients with MM...
  12. pmc Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target
    Dharminder Chauhan
    The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 16:309-23. 2009
    ..Our study therefore validates targeting pDC-MM interactions as a therapeutic strategy to overcome drug resistance in MM...
  13. ncbi request reprint Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Oncogene 24:3121-9. 2005
    ..Our studies therefore demonstrate that LPAAT-beta inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clinical PS-341 resistance and improve patient outcome...
  14. pmc CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells
    Yu Tzu Tai
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:4309-18. 2009
    ..These studies provide direct evidence of the role of CS1 in myeloma pathogenesis, define molecular mechanisms regulating its effects, and further support novel therapies targeting CS1 in MM...
  15. ncbi request reprint Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells
    Dharminder Chauhan
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02215, USA
    Blood 104:2458-66. 2004
    ..Together, these preclinical studies suggest that combining bortezomib with PK may enhance its clinical efficacy, reduce attendant toxicity, and overcome conventional and bortezomib resistance in patients with relapsed refractory MM...
  16. ncbi request reprint BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 136:414-23. 2007
    ....
  17. pmc Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 110:1656-63. 2007
    ..Taken together, these results show that AZD6244 targets both MM cells and OCs in the BM microenvironment, providing the preclinical framework for clinical trials to improve patient outcome in MM...
  18. ncbi request reprint Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, The Department of Medical Oncology, Cancer Biology, Boston Veteran Affairs Healthcare System, Boston, MA, USA
    Blood 101:3606-14. 2003
    ..These studies may therefore allow improved therapeutic use of 2ME2, based upon targeting genes that regulate MM cell growth and survival...
  19. pmc PI3K/p110{delta} is a novel therapeutic target in multiple myeloma
    Hiroshi Ikeda
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Harvard Medical School, Boston, MA, USA
    Blood 116:1460-8. 2010
    ..Our studies therefore show that PI3K/p110delta is a novel therapeutic target in MM and provide the basis for clinical evaluation of CAL-101 to improve patient outcome in MM...
  20. ncbi request reprint The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
    Dharminder Chauhan
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 103:3158-66. 2004
    ..Together, these findings provide the framework for clinical evaluation of CDDO-Im, either alone or in combination with bortezomib, to overcome drug resistance and improve patient outcome in MM...
  21. pmc Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity
    Antonia Cagnetta
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 122:1243-55. 2013
    ....
  22. doi request reprint p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
    Kenji Ishitsuka
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 141:598-606. 2008
    ..These results suggest that LY represents a promising novel targeted approach to improve MM patient outcome both by enhancing the effect of bortezomib and by reducing osteoskeletal events...
  23. ncbi request reprint The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 1:539-44. 2002
    ....
  24. ncbi request reprint Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 64:8746-53. 2004
    ..These findings have clinical significance, because identification of downstream apoptotic signaling after topoisomerase I inhibition will both elucidate mechanisms of resistance and optimize future combination chemotherapy against MM...
  25. ncbi request reprint A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Cell 8:407-19. 2005
    ..Combining NPI-0052 and Bortezomib induces synergistic anti-MM activity. Our study therefore provides the rationale for clinical protocols evaluating NPI-0052, alone and together with Bortezomib, to improve patient outcome in MM...
  26. ncbi request reprint MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Clin Cancer Res 12:5887-94. 2006
    ..The purpose of this study is to delineate the biological significance of IkappaB kinase (IKK) beta inhibition in multiple myeloma cells in the context of bone marrow stromal cells (BMSC) using a novel IKKbeta inhibitor MLN120B...
  27. ncbi request reprint Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma
    Iris Breitkreutz
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 139:55-63. 2007
    ..The present study therefore provides a preclinical rationale for the evaluation of AZD6244 as a potential new therapy for patients with MM...
  28. ncbi request reprint A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:8350-8. 2005
    ....
  29. ncbi request reprint Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 5:221-30. 2004
    ....
  30. ncbi request reprint Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment
    Toshiaki Hayashi
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:7540-6. 2004
    ....
  31. pmc Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:1046-52. 2009
    ..Moreover, IKKbeta inhibitors enhanced bortezomib-induced cytotoxicity. Our studies therefore suggest that bortezomib-induced cytotoxicity cannot be fully attributed to inhibition of canonical NF-kappaB activity in MM cells...
  32. ncbi request reprint Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 138:783-91. 2007
    ..These preclinical studies provide the framework for clinical trials of bortezomib with Perifosine to improve patient outcome in MM...
  33. pmc Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis
    Kenji Ishitsuka
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1794-800. 2005
    ..Taken together, our results provide the preclinical rationale for clinical protocols of HNK to improve patient outcome in MM...
  34. ncbi request reprint Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:2846-52. 2004
    ..1S cells and patient MM cells. Taken together, these results provide the preclinical rationale for the evaluation of SGN-40 as a potential new therapy to improve patient outcome in MM...
  35. pmc Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 109:1220-7. 2007
    ..Our study therefore provides the rationale for clinical protocols evaluating LBW242, alone and together with other anti-MM agents, to improve patient outcome in MM...
  36. ncbi request reprint Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 63:5850-8. 2003
    ..Moreover, they define the functional association of IGF-IR and beta1 integrin in mediating MM cell homing, providing the preclinical rationale for novel treatment strategies targeting IGF-I/IGF-IR in MM...
  37. pmc SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 106:706-12. 2005
    ..Our data, therefore, indicate that R-etodolac circumvents drug resistance in MM cells at clinically relevant concentrations, targets Mcl-1, and can be synergistically combined with Dex...
  38. ncbi request reprint GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment
    Klaus Podar
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Boston, MA 02115, USA
    Blood 103:3474-9. 2004
    ....
  39. ncbi request reprint Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 63:8428-36. 2003
    ..Our data therefore demonstrate for the first time that inhibiting LPAAT-beta induces cytotoxicity in MM cells in the bone marrow milieu, providing the framework for clinical trials of these novel agents in MM...
  40. pmc A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells
    Teru Hideshima
    Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 115:3772-5. 2010
    ....
  41. ncbi request reprint Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
    Toshiaki Hayashi
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 128:192-203. 2005
    ..These studies defined the mechanisms whereby IMiDs trigger NK cell-mediated tumour-cell lysis, further supporting their therapeutic use in MM...
  42. pmc Molecular sequelae of proteasome inhibition in human multiple myeloma cells
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 99:14374-9. 2002
    ..These data provide both insight into the molecular mechanisms of antitumor activity of PS-341 and the rationale for future clinical trials of PS-341, in combination with conventional and novel therapies, to improve patient outcome in MM...
  43. ncbi request reprint FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance
    Hiroshi Yasui
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:7478-84. 2005
    ..These results suggest that FTY720 overcomes drug resistance in multiple myeloma cells and provide the rationale for its clinical evaluation to improve patient outcome in multiple myeloma...
  44. ncbi request reprint Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 101:1530-4. 2003
    ..Inhibition of JNK activity abrogates PS-341-induced MM cell death. These studies identify molecular targets of PS-341 and provide the rationale for the development of second-generation, more targeted therapies...
  45. ncbi request reprint Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 65:11712-20. 2005
    ....
  46. ncbi request reprint The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications
    Nicholas Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2377-80. 2003
    ..These studies, therefore, provide the framework for clinical use of this agent in combination with conventional chemotherapy...
  47. pmc Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
    Renate Burger
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Mol Cancer Ther 8:26-35. 2009
    ....
  48. ncbi request reprint Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway
    Kenji Ishitsuka
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Oncogene 24:5888-96. 2005
    ....
  49. pmc Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma
    Dharminder Chauhan
    The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 111:1654-64. 2008
    ..Taken together, our study provides the preclinical rationale for clinical protocols evaluating bortezomib together with NPI-0052 to improve patient outcome in MM...
  50. pmc Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
    Noopur Raje
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 106:1042-7. 2005
    ..Finally, combination studies of seliciclib with doxorubicin and bortezomib show in vitro synergism, providing the rationale for testing these drug combinations to improve patient outcome in MM...
  51. ncbi request reprint Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib
    Klaus Podar
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:7500-6. 2004
    ....
  52. ncbi request reprint 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
    Tanyel Kiziltepe
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 6:1718-27. 2007
    ..Taken together, these data provide the preclinical rationale for the clinical evaluation of 5-azacytidine, alone and in combination with doxorubicin and bortezomib, to improve patient outcome in MM...
  53. ncbi request reprint beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells
    Deepak Gupta
    Jerome Lipper Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Exp Hematol 30:711-20. 2002
    ..1S); MM cell lines resistant to dexamethasone (MM.1R), melphalan (RPMI8226/LR5), doxorubicin (RPMI8226/DOX40), and mitoxantrone (RPMI8226/ MR20); and MM cells from patients (MM1-MM4)...
  54. pmc Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo
    Makoto Hamasaki
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Mayer 557, 44 Binney St, Boston, MA 02115, USA
    Blood 105:4470-6. 2005
    ..These results, therefore, show that azaspirane both induces MM cell apoptosis and inhibits cytokine secretion in the BM milieu, providing the framework for clinical trials to improve patient outcome in MM...
  55. ncbi request reprint NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 102:2615-22. 2003
    ..Finally, a study using NVP-LAQ824 in a preclinical murine myeloma model provides in vivo relevance to our in vitro studies. Taken together, these findings provide the framework for NVP-LAQ824 as a novel therapeutic in MM...
  56. ncbi request reprint Identification of genes modulated in multiple myeloma using genetically identical twin samples
    Nikhil C Munshi
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston MA 02115, USA
    Blood 103:1799-806. 2004
    ..By identifying genes uniquely altered in MM cells compared with normal PCs in an identical genotypic background, the current study provides the framework to identify novel therapeutic targets...
  57. ncbi request reprint CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 101:2762-9. 2003
    ....
  58. pmc MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts
    Sonia Vallet
    Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 110:3744-52. 2007
    ..Our results therefore show novel biologic sequelae of CCL3 and its inhibition in both osteoclastogenesis and MM cell growth, providing the preclinical rationale for clinical trials of MLN3897 to treat OBD in MM...
  59. doi request reprint The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo
    Hiroshi Ikeda
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 15:4028-37. 2009
    ..We investigated the antitumor effect of murine/human chimeric CD138-specific monoclonal antibody nBT062 conjugated with highly cytotoxic maytansinoid derivatives against multiple myeloma (MM) cells in vitro and in vivo...
  60. pmc The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
    Klaus Podar
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:19478-83. 2006
    ....
  61. ncbi request reprint Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
    Aldo Maria Roccaro
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 66:184-91. 2006
    ..These data, therefore, delineate the mechanisms of the antiangiogenic effects of bortezomib on multiple myeloma cells in the bone marrow milieu...
  62. ncbi request reprint JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells
    Dharminder Chauhan
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:17593-6. 2003
    ..These findings demonstrate that activation of JNK is an obligatory event for the release of Smac during stress-induced apoptosis in MM cells...
  63. ncbi request reprint In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells
    Paola Neri
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 134:37-44. 2006
    ..These data indicate that R-etodolac overcomes resistance to Dex in glucocorticoid-resistant MM cells, providing the framework for clinical trials of R-etodolac combined with Dex, to improve patient outcome in MM...
  64. ncbi request reprint Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival
    Renate Burger
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 123:869-78. 2003
    ..In conclusion, BSF-3 is a novel myeloma growth and survival factor with a potential role in the pathophysiology of the disease...
  65. pmc Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)
    Klaus Podar
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 109:1669-77. 2007
    ....
  66. ncbi request reprint Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
    Yu Tzu Tai
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 65:5898-906. 2005
    ..These results provide the preclinical rationale for clinical trials of CHIR-12.12 to improve patient outcome in multiple myeloma...
  67. pmc Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling
    Marc S Raab
    LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 113:1513-21. 2009
    ..Moreover, we identify p73 as a potential novel therapeutic target in MM. Based on these and previous data, enzastaurin is currently under clinical investigation in a variety of hematologic malignancies, including MM...
  68. ncbi request reprint Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
    Teru Hideshima
    Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Jerome Lipper Multiple Myeloma Center, 44 Binney Street, Boston, MA 02155, USA
    Oncogene 22:8386-93. 2003
    ..Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment...
  69. doi request reprint Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 68:5216-25. 2008
    ..The profile of the anti-MM activity of Aplidin in our preclinical models provided the framework for its clinical testing in MM, which has already provided favorable preliminary results...
  70. ncbi request reprint Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma
    Klaus Podar
    Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Cancer Res 67:1680-8. 2007
    ..Finally, our data suggest that this mechanism may not only be restricted to MM but may also be important in a broad range of malignancies including erythroleukemia and solid tumors...
  71. ncbi request reprint Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:1346-58. 2002
    ..These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival...
  72. ncbi request reprint NF-kappa B as a therapeutic target in multiple myeloma
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:16639-47. 2002
    ..Furthermore, they provide the framework for clinical evaluation of novel MM therapies based upon targeting NF-kappaB...
  73. pmc Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma
    Diana Cirstea
    Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute
    Mol Cancer Ther 9:963-75. 2010
    ..Mol Cancer Ther; 9(4); 963-75. (c)2010 AACR...
  74. doi request reprint Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression
    Jui Dutta-Simmons
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 114:2699-708. 2009
    ..Our data provide evidence for a novel functional link between beta-catenin and Aurora kinase A, underscoring a critical role of these pathways in MM disease progression...
  75. ncbi request reprint Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
    Pierfrancesco Tassone
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 104:3688-96. 2004
    ....
  76. ncbi request reprint Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
    Paul G Richardson
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Blood 100:3063-7. 2002
    ..Our study therefore provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease...
  77. ncbi request reprint [Proteasome inhibitor bortezomib as an anticancer drug]
    Hiroshi Yasui
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, USA
    Tanpakushitsu Kakusan Koso 51:1251-6. 2006
  78. pmc The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
    Xavier Leleu
    Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Blood 110:4417-26. 2007
    ..These results provide understanding of biological effects of Akt pathway in WM and provide the framework for clinical evaluation of perifosine in WM patients...
  79. doi request reprint Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma
    Jing Zhang
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics, Boston, MA 02115, USA
    Cancer Res 69:5082-90. 2009
    ..Our data, therefore, identify Hif-1alpha as a novel molecular target in MM and add another facet to anti-MM drug activity...
  80. pmc Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
    Kihyun Kim
    Department of Medical Oncology, The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Br J Haematol 149:537-49. 2010
    ..Our results therefore support clinical evaluation of AS703026, alone or in combination with other anti-MM agents, to improve patient outcome...
  81. ncbi request reprint Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 63:6174-7. 2003
    ..These findings provide the first evidence that Hsp27 confers PS-341 resistance...
  82. ncbi request reprint The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment
    Boris Lin
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:5019-26. 2002
    ..The demonstrated anti-MM activity of PTK787, coupled with its antiangiogenic effects, provides the framework for clinical trials of this agent to overcome drug resistance and improve outcome in MM...
  83. ncbi request reprint Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu
    Teru Hideshima
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 101:703-5. 2003
    ..These studies therefore identify p38 MAPK as a novel therapeutic target to overcome drug resistance and improve patient outcome in MM...
  84. ncbi request reprint Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, MA 02115, USA
    Oncogene 21:5673-83. 2002
    ..Importantly, they provide the basis for future clinical trials in MM combining conventional or novel agents with strategies designed to neutralize IGF-1...
  85. pmc Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
    Aldo M Roccaro
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA 02115, USA
    Blood 111:4752-63. 2008
    ..Theses studies enhance our understanding of the biologic role of the proteasome pathway in WM, and provide the preclinical basis for clinical trials of combinations of proteasome inhibitors in WM...
  86. pmc In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
    Joseph M Negri
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 147:672-6. 2009
    ..Combinations with dexamethasone (Dex), doxorubicin (Doxo) and bortezomib showed no antagonism. Our study highlights the potential role of the tumour microenvironment in modulating the activity of this drug class...
  87. ncbi request reprint Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib
    Reshma Shringarpure
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 134:145-56. 2006
    ....
  88. ncbi request reprint Novel therapies for multiple myeloma
    Toshiaki Hayashi
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 120:10-7. 2003
  89. ncbi request reprint Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
    Richard LeBlanc
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 103:1787-90. 2004
    ....
  90. ncbi request reprint Proteasome inhibitor therapy in multiple myeloma
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Mol Cancer Ther 4:686-92. 2005
    ....
  91. ncbi request reprint Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications
    Nicholas Mitsiades
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4525-30. 2002
    ..These studies both delineate the mechanism of action of IMiDs against MM cells in vitro and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM...
  92. ncbi request reprint Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
    Richard LeBlanc
    Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 62:4996-5000. 2002
    ....
  93. ncbi request reprint Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
    Lanie K Francis
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, Department of Internal Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 12:6826-35. 2006
    ..Our objective was to determine the effects of the mTOR inhibitor rapamycin and the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on multiple myeloma cells...
  94. ncbi request reprint Proteasome inhibition as a novel therapeutic target in human cancer
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 23:630-9. 2005
    ..This article discusses proteasome inhibition as a novel therapeutic target in cancer and focuses on the development, mechanism of action, and current clinical experience with bortezomib...
  95. doi request reprint Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment
    Alissa Huston
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
    Clin Cancer Res 14:865-74. 2008
    ....
  96. ncbi request reprint Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells
    Mikael Altun
    Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 65:7896-901. 2005
    ..These data suggest that PS-341 targets both normal and immunoproteasome species to a similar extent in myeloma cells...
  97. ncbi request reprint FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 132:698-704. 2006
    ..Our studies therefore demonstrated in vitro anti-MM activity of FQPD and provide the rationale for its in vivo evaluation in animal models and derived clinical trials...
  98. pmc Targeting NF-kappaB in Waldenstrom macroglobulinemia
    Xavier Leleu
    Medical Oncology, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Blood 111:5068-77. 2008
    ..Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-kappaB pathway...